Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:42:48.360Z.
Calculation as of: 2026-10-06T21:42:48.360Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 651b3973db42e019715e3a8a4e975a06fcddd3d3dc4e12dda44c0d1ac22a80ea
PE RATIO
N/A
Market Cap
$17.31M
PE Ratio
N/A
TTM Avg
29275707116178676.00
3Y Avg
6105628756850110.00
5Y Avg
6105628756850110.00
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quantum BioPharma Ltd. (QNTM) | $19.77M | N/A | N/A | N/A | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.42M | N/A | N/A | N/A | N/A |
| NextCure, Inc. (NXTC)vs › | $20.53M | N/A | N/A | N/A | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | N/A | 2.38 | 2.38 | 2.38 |
| P3 Health Partners Inc. (PIII)vs › | $18.41M | N/A | N/A | N/A | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | N/A | N/A | N/A | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.39M | N/A | 49.08 | 49.08 | 49.08 |
| Lipocine Inc. (LPCN)vs › | $17.31M | N/A | 29275707116178676.00 | 6105628756850110.00 | 6105628756850110.00 |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
